Once-Weekly Semaglutide Reduces HbA1c and Body Weight in Patients With Type 2 Diabetes Regardless of Background Common OAD: A Subgroup Analysis From SUSTAIN 2–4 and 10

Diabetes Therapy - United States
doi 10.1007/s13300-020-00796-z
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Pdb87 - A Cost-Of-Control Analysis: Once-Weekly Semaglutide Reduces Cost of Reaching Treatment Targets in Patients With Type 2 Diabetes Mellitus in Norway

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pdb67 - Once-Weekly Semaglutide Versus Dulaglutide for the Treatment of Patients With Type 2 Diabetes in Portugal: A Long-Term Cost-Effectiveness Analysis Based on Sustain 7

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Exenatide Extended-Release: A Once Weekly Treatment for Patients With Type 2 Diabetes

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2014English

Efficacy and Safety of Once-Weekly Semaglutide Monotherapy Versus Placebo in Patients With Type 2 Diabetes (SUSTAIN 1): A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multinational, Multicentre Phase 3a Trial

The Lancet Diabetes and Endocrinology
Internal MedicineEndocrinologyMetabolismDiabetes
2017English

Efficacy and Safety of Once-Weekly Semaglutide Versus Daily Canagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes (SUSTAIN 8): A Double-Blind, Phase 3b, Randomised Controlled Trial

The Lancet Diabetes and Endocrinology
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Frontiers in Pharmacology
Pharmacology
2018English

Clinical Potential of Treatment With Semaglutide in Type 2 Diabetes Patients

Drugs in Context
Molecular MedicinePharmacology
2019English

Once-Weekly Albiglutide in the Management of Type 2 Diabetes: Patient Considerations

Patient Preference and Adherence
PharmacologyHealth PolicyMedicineToxicologySocial SciencesPharmaceutics
2014English

Pdb116 - The Relationship Between Poor Adherence and Hba1c and Weight Changes in Patients With Type 2 Diabetes

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy